Trial Profile
Novel Peptides in Resistant Human Hypertension
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Nesiritide (Primary)
- Indications Hypertension
- Focus Therapeutic Use
- 01 Dec 2016 Status changed from suspended to discontinued.
- 08 Nov 2013 Planned end date changed from 1 Jan 2016 to 1 Nov 2016 as reported by ClinicalTrials.gov record.
- 08 Nov 2013 Status changed from recruiting to suspended as reported by ClinicalTrials.gov record.